FDA Urged to Phase In Quality Metrics Over Two-Year Period
This article was originally published in The Gold Sheet
Executive Summary
Industry consensus emerges: FDA should take it slow with quality metrics, starting with a two-year phase-in period.
You may also be interested in...
FDA To Update Quality Metrics Guidance
It's the only addition to the agency's 2016 agenda.
FDA To Update Quality Metrics Guidance
It's the only addition to the agency's 2016 agenda.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.